Publications

Detailed Information

The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea

DC Field Value Language
dc.contributor.authorKim, Nayoung-
dc.contributor.authorCho, Sung-Il-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorPark, Ji Hyun-
dc.contributor.authorKim, Joo Sung-
dc.contributor.authorSong, In Sung-
dc.contributor.authorJung, Hyun Chae-
dc.contributor.authorKim, Jee Hyun-
dc.date.accessioned2012-05-29T06:33:39Z-
dc.date.available2012-05-29T06:33:39Z-
dc.date.issued2010-01-
dc.identifier.citationDIGESTIVE DISEASES AND SCIENCES; Vol.55 1; 101-110ko_KR
dc.identifier.issn0163-2116-
dc.identifier.urihttps://hdl.handle.net/10371/76555-
dc.description.abstractThe p53 gene has been referred to as `the guardian of the genome` because it controls apoptosis and cell cycle arrest. The purpose of this study was to evaluate the association of p53 codon 72 genetic polymorphism and the p53 immunohistochemistry with Helicobacter pylori-associated gastroduodenal diseases, including gastric cancer. This study included 1,852 subjects: controls and patients with gastric cancer, dysplasia, benign gastric ulcers, and duodenal ulcers (DU). Biallelic polymorphism was genotyped by restriction fragment length polymorphism. Immunohistochemical analysis for the detection of mutant type p53 expression was performed. The frequency of the Pro/Pro allele of the p53 codon 72 was higher in the patients with H. pylori-positive dysplasia than in controls (OR: 2.3, 95% CI: 1.3-4.3), but it was less frequent among patients with a H. pylori-positive DU (OR: 0.5, 95% CI: 0.3-0.8). However, there was no significant association with gastric cancer, including the location, stage, or histological type of gastric cancer. Expression of a mutant type of p53 protein was detected in 6.3% of dysplastic tissues and 26.5% of cancerous tissues compared 0% in the controls. Positive expression was higher in the intestinal type of cancer (34.9%) than in the diffuse type (15.0%; P = 0.001). These results suggest that genetic polymorphism of p53 codon 72 played a role in the determination of H. pylori-associated gastroduodenal diseases, but p53 immunostaining did not correlate with those of the p53 genetic polymorphism analysis.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectp53ko_KR
dc.subjectHelicobacter pyloriko_KR
dc.subjectGastric cancerko_KR
dc.subjectGenetic polymorphismko_KR
dc.titleThe Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Koreako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김나영-
dc.contributor.AlternativeAuthor조성일-
dc.contributor.AlternativeAuthor이혜승-
dc.contributor.AlternativeAuthor박지현-
dc.contributor.AlternativeAuthor김지현-
dc.contributor.AlternativeAuthor김주성-
dc.contributor.AlternativeAuthor정현채-
dc.contributor.AlternativeAuthor송인성-
dc.identifier.doi10.1007/s10620-008-0688-x-
dc.citation.journaltitleDIGESTIVE DISEASES AND SCIENCES-
dc.description.citedreferenceZhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833-
dc.description.citedreferenceKIM JM, 2007, KOREAN J GASTROENTER, V50, P292-
dc.description.citedreferenceMASTUMOTO Y, 2007, NAT MED, V13, P470, DOI DOI 10.1038/NM1566-
dc.description.citedreferenceMurray L, 2006, GUT, V55, P1390, DOI 10.1136/gut.2005.083295-
dc.description.citedreferenceSul J, 2006, CANCER LETT, V238, P210, DOI 10.1016/j.canlet.2005.07.004-
dc.description.citedreferenceMunro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358-
dc.description.citedreferencePerez-Perez GI, 2005, SCAND J GASTROENTERO, V40, P56, DOI 10.1080/00365520410009456-
dc.description.citedreferenceXi YG, 2004, CARCINOGENESIS, V25, P2201, DOI 10.1093/carcin/bgh229-
dc.description.citedreferenceMeek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027-
dc.description.citedreferenceSegal F, 2004, CANCER LETT, V210, P213, DOI 10.1016/j.canlet.2004.01.020-
dc.description.citedreferenceShen HB, 2004, ONCOL REP, V11, P1115-
dc.description.citedreferenceZhang ZW, 2004, DIGEST DIS SCI, V49, P254-
dc.description.citedreferenceSkacel M, 2002, AM J GASTROENTEROL, V97, P2508-
dc.description.citedreferenceGonzalez CA, 2002, INT J CANCER, V100, P249, DOI 10.1002/ijc.10466-
dc.description.citedreferenceHiyama T, 2002, INT J CANCER, V100, P304, DOI 10.1002/ijc.10483-
dc.description.citedreferenceAndersson S, 2001, BRIT J CANCER, V85, P1153-
dc.description.citedreferenceWeston AP, 2001, AM J GASTROENTEROL, V96, P1355-
dc.description.citedreferenceBian YS, 2001, MODERN PATHOL, V14, P397-
dc.description.citedreferenceMcColl KEL, 2000, GASTROENTEROL CLIN N, V29, P687-
dc.description.citedreferenceShepherd T, 2000, GASTROENTEROLOGY, V118, P1039-
dc.description.citedreferencePAPADAKIS EN, 2000, MOL CELL BIOL RES CO, V3, P389-
dc.description.citedreferenceZehbe I, 1999, LANCET, V354, P218-
dc.description.citedreferenceSonoda Y, 1999, J NATL CANCER I, V91, P557-
dc.description.citedreferenceThomas M, 1999, MOL CELL BIOL, V19, P1092-
dc.description.citedreferenceWang YC, 1999, EUR J CANCER, V35, P226-
dc.description.citedreferenceHelland A, 1998, NATURE, V396, P530-
dc.description.citedreferenceHildesheim A, 1998, NATURE, V396, P531-
dc.description.citedreferenceJosefsson AM, 1998, NATURE, V396, P531-
dc.description.citedreferenceStorey A, 1998, NATURE, V393, P229-
dc.description.citedreferenceKim SY, 1998, J IMMUNOASSAY, V19, P251-
dc.description.citedreferenceMobley HLT, 1997, GASTROENTEROLOGY, V113, pS21-
dc.description.citedreferenceDunn BE, 1997, CLIN MICROBIOL REV, V10, P720-
dc.description.citedreferenceYounes M, 1997, DIGEST DIS SCI, V42, P697-
dc.description.citedreferenceLevine AJ, 1997, CELL, V88, P323-
dc.description.citedreferenceCoggi G, 1997, CANCER, V79, P425-
dc.description.citedreferenceDixon MF, 1996, AM J SURG PATHOL, V20, P1161-
dc.description.citedreferenceLabigne A, 1996, INFECT AGENT DIS, V5, P191-
dc.description.citedreferenceHansson LE, 1996, NEW ENGL J MED, V335, P242-
dc.description.citedreferenceSjalander A, 1996, CARCINOGENESIS, V17, P1313-
dc.description.citedreferenceCover TL, 1996, ADV INTERNAL MED, V41, P85-
dc.description.citedreferenceBirgander R, 1996, HUM HERED, V46, P49-
dc.description.citedreferenceGABBERT HE, 1995, CANCER, V76, P720-
dc.description.citedreferenceJIN XM, 1995, CARCINOGENESIS, V16, P2205-
dc.description.citedreferenceLEE A, 1995, EUR J GASTROEN HEPAT, V7, P461-
dc.description.citedreferenceBRITO MJ, 1994, GUT, V35, P1697-
dc.description.citedreferenceHAMELIN R, 1994, GASTROENTEROLOGY, V107, P1012-
dc.description.citedreferenceMOORE JH, 1994, INT J CANCER, V56, P487-
dc.description.citedreferenceJOYPAUL BV, 1993, J PATHOL, V170, P279-
dc.description.citedreferenceKAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085-
dc.description.citedreferenceCORREA P, 1992, CANCER RES, V52, P6735-
dc.description.citedreferenceLIVINGSTONE LR, 1992, CELL, V70, P923-
dc.description.citedreferenceKUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491-
dc.description.citedreferenceMARTIN HM, 1992, INT J CANCER, V50, P1-
dc.description.citedreferenceLEVINE AJ, 1992, CANCER SURV, V12, P59-
dc.description.citedreferenceLOFFELD RJLF, 1991, J PATHOL, V165, P69-
dc.description.citedreferenceHINDS PW, 1990, CELL GROWTH DIFFER, V1, P571-
dc.description.citedreferenceBAKER SJ, 1990, SCIENCE, V249, P912-
dc.description.citedreferenceHESSEY SJ, 1990, GUT, V31, P134-
dc.description.citedreferenceGRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615-
dc.description.citedreferenceLAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31-
dc.description.tc2-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share